

Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, Brazil

Mônica Santos de Melo¹; Lysandro Pinto Borges²; Daniela Raguer Valadão de Souza¹; Aline Fagundes Martins¹; José Melquiades de Rezende Neto³; Anderson Alves Ribeiro⁴; Aryanne Araujo Santos²; Grazielly Bispo da Invenção²; Igor Leonardo Santos Matos²; Kezia Alves dos Santos²; Nicolas Alessandro Alves Souza²; Pâmela Chaves Borges²; Makson Gleydson Brito de Oliveira^{5*}.

¹Department of Education and Health, ³Department of Pharmacy, ⁵Department of Medicine. Federal University of Sergipe, Lagarto, CEP 49400000, Sergipe, Brazil.

²Department of Pharmacy. Federal University of Sergipe, São Cristóvão, CEP 49100000, Sergipe, Brazil.

⁴Federal University of the Southern Border, Erechim, Brazil.

*Corresponding author: Makson Gleydson Brito de Oliveira (PhD, Professor), Department of Medicine, Federal University of Sergipe, Av. Governador Marcelo Déda, 13, CEP 49400-000 Lagarto, Sergipe, Brazil. Phone: 55 (79) 36322080. E-mail: makson_gbo@hotmail.com

Abstract

Background: The exponential growth of COVID-19 cases in Brazil is overloading health systems with overcrowding of hospitals and overflowing intensive care units. Increasing infection rates in health professionals can lead to the collapse of the health system and further worsen the pandemic. The aim of this study was to evaluate the seroprevalence of IgM and IgG for SARS-CoV-2 in health workers in Sergipe, Brazil.

Methods: The targeted tests involved health professionals working on the front line to combat COVID-19. The samples were collected in the month of June, in six hospital units in the state of Sergipe.

Results: 471 health professionals were tested. Of these, 28 workers (5.95%) tested positive for IgM and 64 (13.59%) tested positive for IgG. 9 workers (1.91%) tested positive for IgM and were also positive for IgG.

Discussion: Health workers must be monitored constantly, because if they are infected, they can spread the virus to colleagues, hospitalized patients and even family members.

Conclusion: Knowing the prevalence of antibodies to the virus in health workers is an important measure of viral spread control.

Keywords: SARS-CoV-2, COVID-19, Health workers, Immunofluorescence assays.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1. Introduction

The SARS-CoV-2 infection started in Wuhan, spread further in China and then spread rapidly around the world, classified by the World Health Organization (WHO) on March 11 as a pandemic. This infection causes a severe acute respiratory syndrome, now called COVID-19 (HUANG *et al.*, 2020; ZHU *et al.*, 2020; WHO, 2020).

In addition to respiratory symptoms, gastrointestinal symptoms, impairment of the nervous system and a variety of clinical signs such as fever, cough, shortness of breath, sore throat, malaise too can be seen (SINGHAL, 2020; BENVENUTO *et al.*, 2020). Other symptoms include headache, dyspnoea, hemoptysis, diarrhea and lymphopenia (ROTHAN and BYRAREDDY, 2020).

Infection with SARS-CoV-2 can be aggressive and generates a high rate of hospitalization and, in some cases, hospitalization in Intensive Care Units (BAUD *et al.*, 2020). In Brazil, the exponential growth of COVID-19 cases is overloading health systems with overcrowding of hospitals and overflowing intensive care units. The Unified Health System (SUS) follows the guidelines recommended by the WHO to limit viral spread, isolating people who contract the virus and oriented to compliance with quarantine for people who are at greatest risk (OLIVEIRA *et al.*, 2020).

The orientation of social isolation is not suitable for health workers who work directly to confront COVID-19. Increased infection rates among health workers can lead to the collapse of the health system and further worsen the pandemic (BARRANCO and VENTURA, 2020). In this context, the objective of this study was to evaluate the seroprevalence of IgM and IgG for SARS-CoV-2 in health workers, from different professions, in some health units in the state of Sergipe, Brazil.

2. Methods

The targeted tests involved health professionals working on the front line to combat COVID-19. The samples were collected in the month of June, in six hospital units in the state of Sergipe, in the municipalities of Aracaju, Nossa Senhora do Socorro, Nossa Senhora da Glória and Estância. Personal data including age, gender, address, presence of any comorbidities and symptoms compatible with COVID-19 were gathered through an online questionnaire performed by a health care worker just before blood sample collection. Venous blood samples were collected and centrifuged for serum separation. 471 people were enrolled in this investigation.

The sample chosen for testing for IgG and IgM antibodies to SARS-CoV-2 was human serum. For this purpose, approximately 3 mL of blood was collected from each volunteer. Venous puncture was the chosen technique, with two possibilities for collection sites: the antecubital fossa of the arm or the back of the hand, according to the volunteer's preference. This sample was stored in a refrigerated environment to maintain viable biological properties for analysis.

At the laboratory, the whole blood sample was centrifuged to separate the serum from the other blood components. The centrifuge was programmed to perform 4000 rotations every 1 minute, for 10 minutes. The serum was packed in Eppendorf tubes and kept refrigerated at -20°C until the moment of use. This biological material was analyzed using the ichromaTM COVID-19 Ab test (Boditech Med Inc. Chuncheon, Korea) following the manufacturer's instructions for the detection IgG and IgM antibodies to SARS-CoV-2 by the fluorescence method.

Immunofluorescence assays were performed at the Department of Pharmacy Laboratory (Laboratory of Biochemistry and Clinical Immunology, LaBiC-Imm) at the Federal University of Sergipe (UFS). Anti-SARS-CoV-2 IgM and IgG antibodies were

detected in sera using an in vitro diagnostic test system based on lateral flow sandwich detection immunofluorescence technology (Ichroma2™ COVID-19 Ab in conjunction with an Ichroma™ II Reader, Boditech Med Inc., South Korea) according to the manufacturer's instructions. The immunofluorescence method applied showed a sensitivity of 95.8% and a specificity of 97%. Another work by our group carried out the validation of the method using 120 serum samples collected from 60 real-time reverse transcription polymerase chain reaction (rRT-PCR) confirmed COVID-19 cases, and 60 negative patients at different clinical sites (BORGES *et al.*, 2020).

3. Results

A total of 471 health workers were tested. Of these, 134 were from the Sergipe Emergency Hospital, 33 from the University Hospital and 88 from the Nossa Senhora de Lourdes Maternity, all in the city of Aracaju; 76 of the Regional Hospital of Nossa Senhora da Glória; 66 of the Municipal Hospital of the city of Nossa Senhora do Socorro; 74 of the Regional Hospital of the city of Estância. Of these, 28 workers (5.95%) tested positive for IgM and 64 (13.59%) tested positive for IgG. These results indicate an active or recent infection for IgM reagents and a past infection for IgG reagents. 9 workers (1.91%) serological profile indicating a recent infection that can still be contagious, tested positive for IgM and were also positive for IgG. These data are plotted in Table 1. 370 workers tested non-reactants for the presence of IgM and IgG antibodies to SARS-CoV-2.

INSERT TABLE 1

4. Discussion

The approach to screening health professionals who participated in the study in the health environment depended on the institution's policies, including the number of samples for each sector. In general, healthcare professionals should monitor themselves for fever and

symptoms of COVID-19 and stay home if they are ill. In a report of 48 health workers with confirmed COVID-19 in King County, Washington, 65 percent reported working for an average of two days while exhibiting symptoms of COVID-19 (CHOW *et al.*, 2020). In addition, symptom screening alone did not identify all cases. The survey aims to contribute to map the characteristics related to the work process of these professionals in the midst of the COVID-19 pandemic, as well as the initiatives that are being carried out by managers in health establishments in Brazil.

Based on these data, we can suggest the adoption of safety measures by health professionals in their work processes, focusing mainly on the proper use of Personal Protective Equipment (PPE); as well as Organization of the health establishment in relation to the supply of equipment and supplies, cleaning and disinfection of the environments, in addition to the training and monitoring indicators of its employees (LARSON and LIVERMAN, 2011).

The rapid and accurate diagnosis of COVID-19 contributes to the management of the disease (JIN *et al.*, 2020). The identification of antibodies, mainly IgM and IgG immunoglobulins, produced shortly after infection, can contribute to ensure clinical diagnosis and monitoring of the disease, allowing early intervention and playing a key role in fighting outbreaks (BROADHURST *et al.*, 2016 ; KLUGE *et al.*, 2018). Among the serological tests available are ELISA, CLIA, chemiluminescence, fluorescence, qualitative immunochromatography (PADOAN *et al.*, 2020; LIPPI *et al.*, 2020; KIM *et al.*, 2020; DI MAURO *et al.*, 2020; CARVALHO *et al.*, 2020). The immunofluorescence method was chosen for serological tests performed in this study. Anti-SARS-CoV-2 IgM and IgG antibodies were detected in the serum using an in vitro diagnostic test system based on lateral flow sandwich detection immunofluorescence technology, which presented a sensitivity of 95.8% and specificity of 97%.

Our results show 5.95% IgM reagent antibody, so the choice of serum as a biological sample for evaluation was due to the presence of antibodies. The production of antibodies, mainly IgM, produced quickly after infection, can be a useful tool to assist in the detection of contact with SARS-CoV-2. Thus, using laboratory techniques, the IgM - IgG antibody test allows early intervention with infected people, playing a critical role in fighting outbreaks (BROADHURST *et al.*, 2016; KLUGE *et al.*, 2018). Consistent with the recommendations of the Infectious Diseases Society of America (IDSA), to maximize the predictive value of the serological test, tests with high specificity (≥ 99.5 percent) should be used and the test should be reserved for individuals with high probability pretest of previous infection (HANSEN *et al.*, 2020). Our group recently published a cross-sectional study with stratified sampling on the prevalence of SARS-CoV-2 antibodies in an asymptomatic population in the state of Sergipe. Samples from 3,046 asymptomatic individuals showed a high prevalence of SARS-CoV-2 antibodies (BORGES *et al.*, 2020).

In contrast to data in the literature, detectable antibodies generally take several days to weeks to develop, and the time to detect antibodies varies according to the test (GUO *et al.*, 2020; ZHAO *et al.*, 2020; QU *et al.*, 2020; ZHANG *et al.*, 2020). For example, in a study that considers 38 studies in a systematic review, IgM was detected in 23 percent in one week, 58 percent in two weeks and 75 percent in three weeks; the corresponding detection rates for IgG were 30, 66 and 88 percent (DEEKS *et al.*, 2020). Other studies have suggested that the positive IgG rate approaches 100 percent in 16 to 20 days (CATUREGLI *et al.*, 2020; LONG *et al.*, 2020a; WANG *et al.*, 2020). According to our data, 13.59% of reagent IgG is observed. However, the duration of the detectable antibodies is uncertain (LONG *et al.*, 2020b; IBARRONDO *et al.*, 2020). In one study, it was observed that IgG levels decreased by an average of approximately 75 percent from the acute to the early convalescent phase of the disease and, eight weeks after infection, 40 percent of asymptomatic patients and 13 percent of symptomatic patients had no detectable IgG (LONG *et al.*, 2020b).

Although people should stay at home to reduce the spread of COVID-19, health professionals do the just the opposite. Your job and the longest job hours (due to the increase in the number of infected people hospital) put them at risk of infection (THE LANCET, 2020). Health professionals must be monitored constantly, because if they are infected, they can spread the virus to colleagues, hospitalized patients and even family members. Increased infection rates in healthcare professionals can cause the pandemic to worsen, so an adequate supply of effective PEPs, careful monitoring of all healthcare professionals is essential (BARRANCO and VENTURA, 2020). This is due to the fact that health professionals are currently the most important resource and, therefore, if health professionals are not cared for, the health system is severely damaged.

4. Conclusion

The study showed the prevalence of COVID-19 in health professionals in the state of Sergipe, Brazil. The immunofluorescence assay revealed the antibody rate for SARS-CoV-2 in the studied population. Knowing the prevalence of antibodies to the virus in health workers is an important measure of viral spread control, since they do not comply with the recommendations of social isolation, due to the need to act in the time of a pandemic, and, therefore, are most susceptible to viral contamination and spread.

Author Contributions: All authors have read and agreed to the published version of the manuscript.

Funding: This research was not funded. The authors themselves financed it.

Acknowledgments: The authors dedicate this article to all health professionals who are facing COVID-19. We are eternally grateful to them, and hope that our article can contribute to reducing the number of deaths.

Conflicts of Interest: The authors have declared that there is no conflict of interest.

References

- Barranco R, Ventura F. Covid-19 and infection in health-care workers: An emerging problem. Med Leg J. 2020;88(2):65-66. doi:10.1177/0025817220923694
- Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following Covid-19 infection. Lancet Infect Dis 2020; pii: S1473-3099(20)30195-X. doi: 10.1016/S1473-3099(20)30195-X. [Epub ahead of print].
- Benvenuto, D.; Giovanetti. M.; et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob Health 2020, 1–4. doi: 10.1080/20477724.2020.1725339.
- Borges LP, Martins AF, Melo MS, Oliveira MGB, Neto JMR, Dósea MB et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. Rev Panam Salud Publica. 2020;44:e108. <https://doi.org/10.26633/RPSP.2020.108>
- Broadhurst MJ, Brooks TJG, Pollock NR. Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clin. Microbiol. Rev. 29 (4), 773–793, 2016.
- Carvalho LFdCeS, Nogueira MS. Optical techniques for fastscreening – towards prevention of the coronavirus COVID-19 outbreak. Photodiagnosis and Photodynamic Therapy, 2020.
- Caturegli G, Materi J, Howard BM, Caturegli P. Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case-Control Study. Ann Intern Med 2020.
- Chow EJ, Schwartz NG, Tobolowsky FA, Zacks RLT, Huntington-Frazier M, Reddy SC, Rao AK. Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. JAMA. 2020 May 26;323(20):2087-2089. doi: 10.1001/jama.2020.6637 2020.

209 Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past
210 infection with SARS-CoV-2. *Cochrane Database Syst Rev* 2020; 6:CD013652.

211 Di Mauro G, Scavone C, Rafaniello C, Rossi F, Capuano A. SARS-Cov-2 infection:
212 Response of human immune system and possible implications for the rapid test and treatment.
213 *International Immunopharmacology*, 16 April 2020.

214 Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel
215 Coronavirus Disease (COVID-19). *Clin Infect Dis* 2020; 71:778.

216 Hansen KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America
217 Guidelines on the Diagnosis of COVID-19: Serologic Testing. August 18, 2020
218 <https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/> (Accessed on
219 August 19, 2020).

220 Huang, C.; Wang, Y.; et al. Clinical features of patients infected with 2019 novel coronavirus
221 in Wuhan, China. *Lancet*. 2020, 395, 497-506. doi:10.1016/S0140-6736(20)30183-5

222 Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2
223 Antibodies in Persons with Mild Covid-19. *N Engl J Med* 2020.

224 Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, Wang Y, Cui H, Pan K, Xu A. Diagnostic value
225 and dynamic variance of serum antibody in coronavirus disease 2019. *International Journal of*
226 *Infectious Diseases*, 94, 49-52, 01 may, 2020.

227 Kim YJ, Sung H, Ki CS, Hur M. COVID-19 Testing in South Korea: Current Status and the
228 Need for Faster Diagnostics. *Ann Lab Med*, 40(5): 349-350, 2020.

229 Kluge H, Martin-Moreno JM, Emiroglu N, Rodier G, Kelley E, Vujnovic M, Permanand G.
230 Strengthening global health security by embedding the International Health Regulations
231 requirements into national health systems. *BMJ Global Health* 3, 1–7, 2018.

232 Larson EL, Liverman CT. Preventing Transmission of Pandemic Influenza and Other Viral
233 Respiratory Diseases: Personal Protective Equipment for Healthcare Personnel: Update 2010.
234 Washington (DC): National Academies Press (US); 2011. Available from:
235 <https://www.ncbi.nlm.nih.gov/books/NBK209587/>

236 Lippi G, Salvagno G, Pegoraro M, Militello V, Caloi C, Peretti A, Gaino S, Bassi A, Bovo C
237 and Lo Cascio G. Assessment of immune response to SARS-CoV-2 with fully automated
238 MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clinical Chemistry
239 and Laboratory Medicine (published online ahead of print), 2020.

240 Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
241 COVID-19. Nat Med 2020a; 26:845.

242 Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic
243 SARS-CoV-2 infections. Nat Med 2020b; 26:1200.

244 Oliveira WK, Duarte E, França GVA, Garcia LP. How Brazil can hold back COVID-19.
245 Epidemiol. Serv. Saúde [Internet]. 2020 [cited 2020 Sep 10]; 29(2): e2020044.
246 Available from: [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222020000200200&lng=en)
247 [96222020000200200&lng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222020000200200&lng=en). Epub Apr 27, 2020. [https://doi.org/10.5123/s1679-](https://doi.org/10.5123/s1679-49742020000200023)
248 [49742020000200023](https://doi.org/10.5123/s1679-49742020000200023).

249 Padoan A, Cosma C, Sciacovelli L, Faggian D and Plebani, M. Analytical performances of a
250 chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical
251 Chemistry and Laboratory Medicine (published online ahead of print), 2020.

252 Qu J, Wu C, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory
253 syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

254 Rothan HA and Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
255 (Covid-19) outbreak. J Autoimmun 2020; 109: 102433.

Singhal, T.A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020, 87, 281-286. doi.org/10.1007/s12098-020-03263-6

The Lancet. Covid-19: protecting health-care workers. Lancet 2020; 395: 922.

Wang X, Guo X, Xin Q, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin Infect Dis 2020.

WHO. Pneumonia of unknown cause – China. 05 January 2020. <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/>

Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019. J Infect Dis 2020; 222:183.

Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020.

Zhu, H.; Wang, L.; et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Translational Pediatrics 2020, 9, 51-60. doi: 10.21037/tp.2020.02.06

Table 1: Seroprevalence of IgM and IgG for SARS-CoV-2 in health workers in six hospital units Sergipe, Brazil

Site	Valid samples	IgM reagent	IgG reagent	IgM and IgG reagent	No reagent
SEH	134	1	13	1	119
NSLM	88	8	5	0	75
RHNSG	76	4	4	3	65
MHNSS	66	9	12	5	40
UH	33	2	7	0	24
RHE	74	4	23	0	47
Total	471	28	64	9	370
Total (%)	100%	5,95%	13.59%	1,91%	78,55%

SEH: Sergipe Emergency Hospital; **NSLM:** Nossa Senhora de Lourdes Maternity; **RHNSG:** Regional Hospital of Nossa Senhora da Glória; **MHNSS:** Municipal Hospital of Nossa Senhora do Socorro; **UH:** University Hospital; **RHE:** Regional Hospital of Estância.